Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 7;7(12):899-907.
doi: 10.1002/jgh3.13000. eCollection 2023 Dec.

Comprehensive systematic review and pooled analysis of real-world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment

Emi Khoo  1   2   3 , Andrew Lee  1   2 , Teresa Neeman  4 , Yoon-Kyo An  1   2   3 , Jakob Begun  1   2   3
Affiliations

Comprehensive systematic review and pooled analysis of real-world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment

Emi Khoo et al. JGH Open. .

Abstract

Background and aim: Pouchitis is a common complication after restorative ileal pouch-anal anastomosis following proctocolectomy for ulcerative colitis. Antibiotic-dependent or antibiotic-refractory chronic pouchitis (CP), which is a common cause of pouch failure affecting 15-20% of patients, is challenging to treat. The efficacy of second-line immunomodulator and biologic therapy remains poorly defined. We present a pooled analysis of real-world efficacy data from peer-reviewed full-text manuscripts, focusing on immunomodulator and biologic therapies in CP.

Methods: Embase and PubMed databases were searched for full-text articles describing the treatment of CP. We performed a systematic review and pooled analysis of published studies to assess the efficacy of immunomodulators, including thiopurines and methotrexate, and biologics including antitumor necrosis factor, anti-integrin, and interleukin-12/23 antagonists. Clinical and endoscopic response and remission rates were combined for pooled analyses. Rates of treatment discontinuation and safety were also assessed.

Results: Pooled analysis comprised 20 full-text articles (485 patients). Overall clinical response rate was 46% (95% CI: 35-59%) and clinical remission rate was 35% (95% CI: 21-52%). Overall endoscopic response and remission rates were 41% (95% CI: 18-68%) and 15% (95% CI: 5-39%), respectively. Individual agents' safety profile was reassuring, with vedolizumab being the most favorable.

Conclusion: The real-world efficacy data of immunomodulators in the treatment of CP is insufficient. Vedolizumab and ustekinumab appeared effective and safe for CP, whereas anti-TNFs showed higher rates of adverse events. The high heterogeneity within the studies is attributed to the real-world study design, obfuscating drug efficacy comparisons across the studies. Further studies are required to define the comparative effectiveness of available treatments of CP.

Keywords: biologic therapies; chronic pouchitis; immunomodulator.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flowchart illustrating the search process.
Figure 2
Figure 2
Forrest plots of the primary and secondary outcomes comparing the efficacy of each intervention: (a) clinical response, (b) clinical remission, (c) endoscopic response, and (d) endoscopic remission.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Segal JP, Ding NS, Worley G et al. Systemic review with meta‐analysis: the management of chronic refractory pouchitis with an evidence‐based treatment algorithm. Aliment. Pharmacol. Ther. 2017; 45: 581–592. - PubMed
    1. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population‐based cohort. Am. J. Gastroenterol. 2012; 107: 1228–1235. - PubMed
    1. Lepisto A, Luukkonen P, Jarvinen HJ. Cummulative failure rate of ileal pouch‐anal anastomosis and quality of life after failure. Dis. Colon Rectum. 2002; 45: 1289–1294. - PubMed
    1. Barnes EL, Herfarth HH, Sandler RS et al. Pouch‐related symptoms and quality of life in patients with ileal‐pouch‐anal anastomosis. Inflamm. Bowel Dis. 2017; 23: 1218–1224. - PMC - PubMed
    1. Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis. Cochrane Database System. Rev. 2019; 5. doi:10.1002/14651858.CD001176.pub5 - DOI - PMC - PubMed